CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support
- CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data
- Awarded a €2.5M European Innovation Council (EIC) Accelerator grant to prepare for Phase II development in pediatric Fragile X Syndrome (FXS) patients
- CONNECTA leads innovation in neurodevelopmental therapies as a unique European biotech advancing a clinical-stage FXS program
Barcelona, Spain – 9 September 2025 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, today announced the launch of studies for the pediatric development program of CTH120, an investigational FXS treatment, following positive results from the Phase I trial.
